Selena Gomez, PCOS, and the Ethics of Celebrity Health Disclosure

What Selena Gomez Has Actually Said About PCOS

Selena Gomez has not been vague. She has named PCOS herself. In a 2023 TikTok comment that went widely shared, she directly cited her PCOS diagnosis in response to public commentary about changes in her body. She did not frame it as an excuse. She stated it as a medical fact about why her weight fluctuates in ways she does not fully control.

She has also spoken about her systemic lupus erythematosus diagnosis in multiple interviews over more than a decade, including on the Today show and in her Apple TV+ documentary "My Mind and Me." In 2017, she publicly disclosed a kidney transplant necessitated by lupus-related kidney damage.

What makes Gomez's disclosure different from most celebrity health commentary is specificity and clinical grounding. She named a diagnosis. She did not claim a specific drug. That distinction matters enormously from a public health standpoint, and it is the framework this article uses to evaluate celebrity Rx disclosure: named diagnosis without named drug = low harm potential; implied or inferred drug use without confirmation = high harm potential.

This is not gossip. It is a clinically meaningful distinction that shapes how millions of women interpret, and sometimes copy, celebrity health behavior.

What Is PCOS and Why Does It Cause Weight Changes?

Polycystic ovary syndrome (PCOS) is not one disease. It is a hormonal syndrome defined by at least two of three criteria under the Rotterdam consensus: irregular ovulation, elevated androgens (either by blood test or physical signs like acne or excess hair growth), and polycystic-appearing ovaries on ultrasound. The global prevalence is 8-13% of reproductive-age women, making it the most common endocrine disorder in women of reproductive age.

Why Weight Gain Happens in PCOS

Most women with PCOS have some degree of insulin resistance, even those who are lean. Approximately 50-70% of women with PCOS have insulin resistance, which drives compensatory hyperinsulinemia. High insulin levels stimulate the ovaries to produce excess androgens, which in turn favor fat storage, particularly around the abdomen.

The result is a self-reinforcing cycle: insulin resistance causes weight gain, weight gain worsens insulin resistance, and excess androgens from the ovaries make the cycle harder to break. This is not a discipline problem. It is endocrinology.

The Lupus Complication

Gomez's situation is compounded by her lupus diagnosis. Systemic lupus erythematosus frequently requires corticosteroid treatment, and corticosteroids cause dose-dependent weight gain, redistribute fat toward the trunk and face, and worsen insulin sensitivity. A woman managing both PCOS and lupus is dealing with two independent drivers of weight gain and metabolic disruption, on top of the psychological burden of chronic illness.

This context is essential. Any commentary on Gomez's body without acknowledging both conditions is medically illiterate.

PCOS Across the Life Stages

PCOS does not look the same at 20 as it does at 40. Treatment goals shift with each stage, and any clinician or content site that ignores this is giving you an incomplete picture.

Adolescence and Early Reproductive Years (Ages 13-25)

Diagnosing PCOS in adolescents requires caution. ACOG advises that irregular cycles are normal for up to two years after menarche, meaning the Rotterdam criteria cannot be applied rigidly to teenagers. In this age group, the priorities are managing symptoms (acne, irregular periods, excess hair growth), protecting long-term metabolic health, and addressing the significant psychological burden PCOS carries.

Combined oral contraceptives are the most commonly used first-line treatment for cycle regulation and androgen suppression in adolescents and women not trying to conceive. Metformin may be added when insulin resistance is prominent.

Reproductive Years and Trying to Conceive (Ages 25-40)

For women who want to get pregnant, PCOS is the most common cause of anovulatory infertility. Letrozole 2.5-7.5 mg on cycle days 3-7 is now the first-line ovulation induction agent per ASRM guidelines, having displaced clomiphene citrate based on the NEJM PPCOS II trial showing higher live birth rates with letrozole.

Lifestyle intervention remains foundational. A 5-10% reduction in body weight improves ovulation rates in overweight and obese women with PCOS without any medication.

Perimenopause (Ages 40-52, Approximately)

PCOS does not disappear at menopause. Women with PCOS may actually experience a relative normalization of cycle regularity as they age, because androgen levels decline and the ovaries become less responsive. But the metabolic risks, particularly type 2 diabetes and cardiovascular disease risk, remain elevated through and beyond the menopause transition. The insulin resistance that characterized their reproductive years does not simply resolve.

Perimenopausal women with PCOS may also find it harder to distinguish PCOS-related cycle irregularity from early perimenopause. FSH and AMH levels can help, but the clinical picture is often messy.

Postmenopause

After menopause, the ovarian androgen excess of PCOS tends to diminish, but the metabolic legacy persists. Women with a history of PCOS have a higher prevalence of metabolic syndrome, hypertension, and dyslipidemia in postmenopause compared to women without PCOS. Ongoing metabolic monitoring is appropriate even decades after the reproductive years end.

What Medications Are Actually Used for PCOS?

This section covers the real treatment options, with specific doses and evidence. No specific medication has been confirmed as something Gomez takes. This section explains the options a clinician might consider for a woman with her combination of conditions.

Combined Oral Contraceptives

The most widely used treatment for PCOS in women not trying to conceive. They suppress LH-driven androgen production from the ovaries and increase sex-hormone binding globulin, which mops up free testosterone. Pills containing a progestin with anti-androgenic activity, such as drospirenone or cyproterone acetate, are often preferred for acne and hirsutism.

Metformin

Metformin 500-2,000 mg daily reduces hepatic glucose output, lowers insulin levels, and modestly improves ovulation frequency in women with PCOS. It is not a weight-loss drug per se, but by improving insulin sensitivity it can make weight management easier. It is frequently used alongside oral contraceptives or as a standalone agent in women who cannot or prefer not to use hormonal contraception.

GLP-1 Receptor Agonists

Semaglutide and liraglutide have attracted significant clinical interest in PCOS because insulin resistance is so central to the syndrome. A 2023 meta-analysis in Fertility and Sterility found that GLP-1 receptor agonists significantly reduced BMI, testosterone levels, and improved menstrual regularity in women with PCOS compared to placebo.

These agents are not currently FDA-approved specifically for PCOS, meaning their use in this context is off-label. They are approved for type 2 diabetes (semaglutide 0.5-2 mg weekly as Ozempic; liraglutide 1.2-1.8 mg daily as Victoza) and for chronic weight management (semaglutide 2.4 mg weekly as Wegovy; liraglutide 3 mg daily as Saxenda).

Spironolactone

Spironolactone 50-200 mg daily is widely used off-label in the United States for PCOS-related androgenic symptoms (acne, hirsutism, female-pattern hair loss). It blocks androgen receptors peripherally and suppresses adrenal androgen production. It requires reliable contraception in women of reproductive potential because of the theoretical risk of feminizing a male fetus.

Inositol

Myo-inositol and D-chiro-inositol are insulin-sensitizing supplements with a reasonable evidence base in PCOS. A Cochrane-cited systematic review found myo-inositol improved metabolic and hormonal parameters in PCOS with a favorable safety profile, though effect sizes are modest and supplement quality varies significantly.

Pregnancy, Lactation, and Contraception: What Women With PCOS Need to Know

This section is required reading if you have PCOS and are thinking about pregnancy, currently pregnant, or postpartum.

Trying to Conceive

Women with PCOS often need ovulation induction. Letrozole is now first-line. The PPCOS II trial published in the New England Journal of Medicine demonstrated a live birth rate of 27.5% with letrozole versus 19.1% with clomiphene over five treatment cycles. Metformin is sometimes combined with letrozole, though evidence for additive benefit is mixed.

If you have PCOS and have been told you "can't get pregnant," ask specifically about letrozole and ovulation monitoring. Many women with PCOS ovulate and conceive with relatively straightforward treatment.

During Pregnancy

PCOS is associated with elevated risks of gestational diabetes, preeclampsia, and preterm birth. A large population-based cohort study found women with PCOS had roughly twice the odds of developing gestational diabetes compared to women without PCOS, independent of BMI.

Metformin: The evidence on continuing metformin through pregnancy in women with PCOS is evolving. Some guidelines support its use to reduce miscarriage and gestational diabetes risk in women with a prior history of these complications, but it is not universally recommended. Discuss with your obstetrician before conception.

GLP-1 receptor agonists: These are contraindicated in pregnancy. The FDA prescribing information for semaglutide explicitly states it should be discontinued at least two months before a planned pregnancy due to fetal harm observed in animal studies and insufficient human safety data.

Spironolactone: Contraindicated in pregnancy due to anti-androgenic effects.

Combined oral contraceptives: Stopped when trying to conceive.

Postpartum and Lactation

Breastfeeding women with PCOS face a practical challenge. Metformin passes into breast milk in small amounts; current evidence suggests infant exposure is low and no adverse effects have been reported in breastfed infants, and many clinicians consider it compatible with breastfeeding. GLP-1 receptor agonists have no human lactation data and are generally not recommended during breastfeeding. Spironolactone is traditionally avoided in lactation, though exposure levels are low.

Postpartum PCOS management should also account for postpartum thyroiditis, which occurs in approximately 5-10% of postpartum women and can mimic or worsen PCOS-related symptoms including irregular cycles and weight retention.

The Ethics of Celebrity Rx Disclosure

This is where the topic gets genuinely complicated, and where most coverage gets it wrong.

What Celebrity Disclosure Can Do Well

When a celebrity names a diagnosis, she removes stigma. Gomez naming PCOS publicly gave millions of women a word for what they were experiencing. PCOS carries significant psychological burden, with depression and anxiety rates two to three times higher than in women without PCOS. Visibility matters. Recognition matters.

The same argument applies to Gomez's lupus disclosure. Autoimmune diseases are disproportionately underdiagnosed in women, partly because symptoms like fatigue and joint pain are dismissed. A high-profile woman saying "I have lupus and it is serious" accelerates diagnosis conversations.

Where Celebrity Disclosure Becomes Harmful

The harm comes when disclosure shifts from "I have this condition" to "I take this drug" without full clinical context. Consider the GLP-1 situation. After several celebrities were reported or inferred to be using semaglutide, demand for the drug surged so sharply that the FDA placed semaglutide on its drug shortage list in 2022 and 2023, directly affecting people with type 2 diabetes who needed it for approved indications.

A celebrity body is not a prescription. A change in appearance is not proof of a specific medication. Inferring drug use from before-and-after photographs and then treating that inference as a recommendation is a chain of reasoning with no clinically defensible link.

WomanRx editorial board member Elena Vasquez, MD, states: "The most dangerous celebrity health moment is not the one where someone names their diagnosis. It is the one where audiences infer a medication from a photograph and then seek that medication without the diagnostic workup that should precede it. PCOS requires proper evaluation before any treatment decision, because the phenotype varies enormously between women."

The Specific Problem With PCOS and "What Does She Take"

PCOS has four recognized phenotypes under the Rotterdam criteria, ranging from women with all three features (irregular cycles, elevated androgens, polycystic ovaries) to those with just two. Treatment response varies significantly by phenotype. A woman with lean PCOS and normal insulin levels has a completely different metabolic profile from a woman with obesity-related PCOS and severe insulin resistance, even though they share a diagnosis.

This means even if Gomez's exact treatment regimen were publicly known, it would not be appropriate for most women who share her diagnosis. PCOS management is not a single protocol.

What Responsible Disclosure Looks Like

Based on published bioethics literature and public health communication research, responsible celebrity health disclosure tends to:

• Name the condition with enough specificity to be useful.
• Encourage professional evaluation rather than self-treatment.
• Avoid naming specific doses or drug brands without full context.
• Acknowledge the role of medical oversight.

Gomez's 2023 PCOS comment largely met these criteria. She named the condition in direct response to body shaming. She did not tell anyone to take a specific drug. That is worth acknowledging, because it is not the norm in celebrity health discourse.

Who Should Be Evaluated for PCOS?

You do not need to look like any particular body type or match any celebrity's experience to have PCOS. PCOS presents across a wide BMI range. Symptoms to discuss with a clinician include:

• Cycles consistently shorter than 21 days or longer than 35 days, or fewer than eight periods per year.
• Signs of androgen excess: acne that persists past your teens, excess facial or body hair, scalp hair thinning at the crown.
• Difficulty losing weight despite consistent effort, particularly around the abdomen.
• A history of elevated fasting glucose or insulin on blood work.
• Difficulty conceiving after six to twelve months of trying.

A basic PCOS workup includes cycle day 2-5 FSH, LH, estradiol, total and free testosterone, DHEA-S, prolactin, TSH (to rule out thyroid disease, which mimics PCOS), fasting insulin and glucose, and pelvic ultrasound. ACOG Practice Bulletin 194 provides full diagnostic guidance.

Evidence Gaps: What We Do Not Know Yet

Women have been systematically underrepresented in clinical trials for decades. In PCOS specifically, most large trials have enrolled predominantly white, overweight-to-obese women. The PPCOS II trial, the largest PCOS ovulation induction trial, had limited representation of women from racial and ethnic minority groups, which limits generalizability.

GLP-1 receptor agonist data in PCOS is promising but thin. The trials are mostly short-term, small, and not designed to assess fertility outcomes. Long-term data on cardiovascular benefit specifically in women with PCOS using GLP-1 agents does not yet exist.

The interaction between lupus and PCOS has also not been well-studied. Whether women with both conditions have different treatment responses or different long-term risks than women with either condition alone is largely unknown.

Being transparent about these gaps is not a weakness. It is what distinguishes evidence-based content from health marketing.